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Abstract
Background: A topic of great concern in bioethics is the medical research conducted in poor
countries sponsored by wealthy nations. Western drug companies increasingly view Latin America
as a proper place for clinical research trials. The region combines a large population, modern
medical facilities, and low per capita incomes. Participants from developing countries may have little
or non alternative means of treatment other than that offered through clinical trials. Therefore, the
provision of a valid informed consent is important.
Methods: To gain insight about some aspects of the informed consent procedure in a major
cancer centre in Mexico, we conducted a three-step evaluation process: 1) a ten point multiple
choice survey questionnaires, was used to explore some aspects of the patients' experiences during
the informed consent process, 2) researchers' knowledge about specific aspects of the informed
consent was evaluated in this study using survey questionnaires; and 3) the comprehensibility,
readability and number of pages of the consent forms were analysed. The socioeconomic and
educational level of the patients, were also considered. Results were reported using a numerical
scale.
Results: Thirty five patients, 20 doctors, and 10 individuals working at the hospital agreed to
participate in the study. Eighty three percent of the patients in the study were classified as living in
poverty; education level was poor or non existent, and 31% of the patients were illiterate. The
consent forms were difficult to understand according to 49% of the patients, most doctors agreed
that the forms were not comprehensible to the patients. The average length of the IC documents
analysed was 14 pages, and the readability average score was equivalent to 8TH Grade.
Conclusion: The results presented in this work describe some relevant characteristics of the
population seen at public health care institutions in Mexico. Poverty, limited or no education, and
the complexity of the information provided to the patients may question the validity of the
informed consent procedure in this group of patients.
Background
All achievements of modern medicine stem from research.
Advances, now taken for granted, were developed through
experimentation, which was conducted, for the most part,
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according to the standards and theories available at the
time that it was conducted [1]. Even though guidelines
and rules have been implemented, the setting in which
research takes place is constantly changing, and some-
times both conducting research and choosing not to con-
duct it can be morally problematic [2-6].
Currently, a topic of great concern in medical ethics is the
biomedical research being sponsored by wealthy nations
and conducted in underprivileged countries. Unequal
resource distribution between external research sponsors
and health care facilities in developing countries may
increase the hazard of exploitation [7].
As has been reported for HIV/AIDS clinical trials in Africa,
developing countries may have different motivations to
take part in a clinical trial as prospective participants may
have little or no alternative means of receiving health care
for their conditions, other than that offered through clin-
ical trials; therefore, enforcement of ethical research pro-
cedures represents a major goal for clinical research [7-
13].
The 'consent procedure' is associated with the origins of
bioethics and is considered that it is a necessary, but not
sufficient, condition for research on a subject to be ethical
[14-18].
The rationale of the IC according to some, is based on the
legal and ethical right that a patient has to be fully
informed before he/she accepts what happens to his/her
body; and from the ethical duty that physicians have to
involve patients in the decision making process regarding
their treatment. However, according to others, the IC is
the result of changes in the traditional relations of trust
[18].
The validity of the informed consent assumes an inde-
pendent, competent [19] individual, whom freely gives a,
reasoned approval for a given procedure [20-22]. The
patients' right to be fully informed is increasingly her-
alded as the ethical panacea, preventing the potential dan-
ger of paternalistic autocratic practices [15].
There are many distinct conceptions of individual auton-
omy, and their ethical importance varies; ethics commit-
tees in the West consider the individual autonomy the
main moral principle in the decision-making process of
the patients; its influence tends to over-ride the value of
other bioethical principles [18-21]. In contrast, ethical
systems in non-Western cultures may be less dialectical,
less analytical, and more sensitive to family or community
consensus than to individual autonomy [22-25].
A central point in either scenario is the need to compre-
hend the information received before an independent
consent is given; consequently, to ensure a sufficient level
of understanding of the procedure represents an impor-
tant challenge during the informed consent procedure.
Experimental cancer treatments require special considera-
tions from different perspectives; many treatments are
expensive, and often require to be given for long periods
of time. Frequently, during the course of the disease,
standard approved treatments are exhausted; therefore,
most cancer patients will eventually participate in experi-
mental clinical trials [26,27].
For patients living in most developing countries, the
absence of universal health care coverage results in com-
plex difficulties to access expensive medical treatments; in
consequence, front line cancer chemotherapy may not be
available for an important number of patients, except if
enrolled in a clinical trial [12,28,29].
Nowadays, clinical studies for cancer treatment world-
wide are mostly funded by pharmaceutical companies
[30,31]. At the Instituto Nacional de Cancerología
(INCan), industry-funded trials account for more than
fifty percent of research activities, hence, the population
attending this institution benefits from treatments other-
wise not available to them [32]. These patients' economic,
social, and educational characteristics, as well as their
medical condition, dependency situation, and despera-
tion for any treatment that may offer them any hope, are
paradigmatic characteristics of a vulnerable population
[33].
The value and importance of a valid informed consent (in
any research involving human beings, and these patients
in particular) is without question. In Mexico, the need of
an informed consent for patients involved in clinical
research is required by law; in research sponsored by inter-
national pharmaceutical companies, a careful monitoring
of the informed consent procedure is done by interna-
tional Clinical Research Organizations (CRO), according
to the request of the authorities from the countries of the
different sponsors [34,35].
The informed consent forms given to patients enrolled in
these research studies are standard forms provided by the
sponsor companies. Often, the studies are multicenter tri-
als, or have been previously undertaken in developed
countries; therefore, the consent forms are multipage,
translated documents, with uniform criteria for all the
centers where the trial is being conducted. The IC proce-
dure, through complex documentation, fulfills ethical,
regulatory and legal requirements, both for Mexican and
International authorities. For the international sponsoredBMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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clinical research, clinical research organisations (CROs)
have an important role making sure that the informed
consent procedure is applied according to Good Clinical
Research Practices. However, non conclusive information
suggest that research participants frequently, may not
understand the information presented during the
informed consent procedure; therefore, different method-
ologies to improve understanding during the IC proce-
dure have been tried, however, further research is needed
[36-38].
The purpose of this paper is to assess some aspects of the
IC procedure from different perspectives in order to detect
possible ways to improve the procedure in the near future,
including: 1) experiences regarding the IC of a group of
patients enrolled in clinical research trials, 2) doctors' per-
ception about the consent procedure, of international
sponsored trials and 3) review of several features from
randomly selected consent forms.
Methods
With the purpose of assessing clinical research partici-
pants' experiences during the informed consent process in
the setting of a cancer centre in Mexico; we conducted a
prospective analysis of some aspects of the procedure. The
study design included the evaluation of ten different con-
sent forms provided by international sponsors and the use
of questionnaires to evaluate the informed consent (IC)
procedure for patients enrolled in clinical research trials.
The protocol had been approved by the hospital Ethics
Committee, requiring only a verbal consent for participa-
tion of the different subjects in the study.
Patients
During a three week period, patients present for routine
follow up at the outpatient clinic of the hospital were
invited to participate in the survey; after informing the
purpose and nature of the study, a verbal consent was
obtained. All the participating patients received a short
letter, which was read with them (Additional file 1); and
a ten question printed survey was applied. After explain-
ing the procedure, free alone time or in the company of
their family was provided to answer the questionnaire
(Additional file 2).
Survey questionnaires included selected responses to
statements (yes or no) and/or multiple options for
answers. Participants were able to select more than one
statement and to add comments to selected questions.
Socio-economic and educational level of the patients was
established. A six point evaluation program (family
income, occupation, nutrition, living conditions, place of
residence and presence of sick people within the family)
used by social workers on all patients admitted to the
INCan. The results of the social workers' evaluation, and
some medical and demographic characteristics, were
obtained from medical records.
Results were expressed numerically, as well as a percent-
age, along with relevant characteristics presented in the
results.
Doctors
Doctors were invited to participate through personal com-
munication. During the initial approach, the purpose of
the study was explained, in addition a description was
sent to them by e-mail. In a second personal interview,
they were given the option of answering the questionnaire
either in a printed or electronic version. Consent for par-
ticipation was verbal and a three week period was pro-
vided before collecting the forms (Additional file 3).
Informed consent documents
A critical reading of ten different consent forms sent to be
approved by the Ethics Committee of the Instituto
Nacional de Cancerología was done by a single rater; the
documents were read both in English and their translated
versions in Spanish. Several points were individually
assessed in all the documents: 1) number of pages, 2) ful-
filment of the basic elements of informed consent (expla-
nation of the purpose of the research, expected duration,
risks, benefits, alternative procedures, confidentiality,
compensations, contact person, statement of voluntary
participation), 3) original language of the CF (the first let-
ter of the original language of the document was recorded,
i.e. 'E" for English). A visual numerical scale evaluation
was done by a single rater (there is no inter-rater reliability
data) for the assessment of the following aspects: 4) accu-
racy of the translation, 5) use of medical or scientific
terms, 6) use of language not used by non-medical indi-
viduals, and 7) medical language that may be difficult to
understand by average individuals seen at the institution.
Results represent averages of scores (for question 4, 1 was
poor and 10 was good and for questions 5, 6, and 7, 1
meant few and 10 many), and 8) readability score was
assessed according to sample paragraphs published by
Paasche-Orlow and based on the Flesch–Kincaid readabil-
ity scale, the method developed by Fry [39,40] (Addi-
tional file 4 (part A))
The comprehensibility of the consent form was also qual-
itatively scrutinized with the help of ten individuals: two
nurses, two secretaries, three ambulance drivers, two
social workers, and one medical resident. Selected consent
forms were read by these individuals after the sponsor's
name and study drug(s) were blanked out. A standard set
of questions were asked after reading the forms; the
responses by most of the individuals are described in
Additional file 4 (part B).BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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Results
Patients
An invitation letter previously approved by the Ethics
Committee was given to fifty patients (Additional file 1),
of which only 35 agreed to participate. Most of the
patients had been attending the hospital for two to five
years. All of the patients had advanced cancer (data not
shown) and failed to respond to standard therapy; and
were participating in Phase II or III clinical trials involving
chemotherapy, radiotherapy, and immunotherapy or tar-
geted therapies.
All the patients were or had been enrolled in trials
financed by international pharmaceutical companies. The
studies comply with all of the requirements of health and
hospital authorities.
Socioeconomic factors
A review of participating patients' medical records showed
that most of them lived in rural or low income urban
areas. Eighty-three percent of the patients were classified
as living in poverty, based on a six point socioeconomic
evaluation (see Figure 1). The income of most of the
patients admitted to the hospital was found to be less than
one to two times the minimum wage, $4.00 U.S./day and
seven of the enrolled patients were living on less than one
dollar per day. Their educational level was also estab-
lished to be poor, 31% of the patients were illiterate, 29%
did not finish grade school, only 20% attend up to grade
school, and seven (20%) had additional education (Table
1).
Enrolment into the clinical trials and IC procedure
All the patients had been undergoing treatment at the
institution for more than two years; most of them had had
several doctors in charge of their treatment. At the time of
enrolment in the clinical trial, their treating physician had
invited them to participate (86%). Their physician
explained about the treatment in all the cases and asked
them to read and sign the informed consent, always
opened to questions. After signing the informed consent,
only two patients knew what the document explained
Patients' population Figure 1
Patients' population. Any circumstances in which and individuals are in a position of dependency (research subjects, elderly, 
indigenous, poor people, dying patients) makes them potentially vulnerable.BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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about the treatment risks and benefits (6%). In response
to the specific question about why they were asked to sign
the informed consent, 16 of 35 patients (46%) answered
"to receive free treatment", 29% responded that it was to
free the hospital and doctors of any responsibility. Inter-
estingly enough, none of the patients thought that the
purpose of the consent was to protect their rights as a
patient, even though this answer was part of the question-
naire (Table 2).
The document was read by only 57% of the patients,
though the main reason for not reading the consent was
illiteracy (31%). Three patients (8%) did not read the con-
sent form because they considered that "the explanation
their physicians provided was sufficient for them to
decide to sign the document". Most of the patients read
the document only once, outside of their doctor's office,
at the hospital, and decided to participate in the study in
less than an hour (data not shown, this question was
asked directly to the patients). Thirty three patients
decided to participate in the study with the help of some-
one from their family and only two patients read and
signed the document on their own. Only eight of the
patients who read the document believed that their under-
standing of the treatment proposal improved after reading
the document (Table 2).
Each and every one of the patients who read the docu-
ment thought that it was lengthy. Many patients consid-
ered that it was difficult to understand and that the
document had many words of which they "didn't know
the meaning". Almost half of the patients believed that
signing the document was mandatory before they could
receive treatment (as a "requirement", not as a right to
know). Many thought that their doctor's explanation was
easier to understand than the informed consent docu-
ment. The reasons that were cited as the most important
for enrolling in trials included: improving their health,
having access to an otherwise inaccessible treatment, and
because their doctor thought it was the best option for the
patient (Table 2).
Doctors
Participation and knowledge about the IC
Participation of physicians in the survey was limited, only
twenty (out of 50 doctors involved in clinical research tri-
als at the institution) answered the questionnaire. All par-
ticipating doctors knew that their patients had to be
Table 1: Characteristics of the Patients in the Study
Characteristic Number Average
Number of Patients 35
Age (yrs)
Median (range) 59 (27–92)
Mean 57.9
Gender
Female 20
Male 15
Schooling
None 11 31
Grade School Incomplete 10 29
Grade School Complete 7 20
High School Incomplete 4 11
High School Complete 3 9
College/University 0 0
Place of Residence
Urban 11 31
Rural 24 69
Average Family Income
Less than 1 minimum wage 12 34
2–5 minimum wage 15 43
More than 5 minimum wages 8 23
Tumor Site**
Head and Neck 8 23
Prostate 4 11
Malignant Melanoma 6 17
Breast Cancer 8 23
Cervical Carcinoma 9 26
*Minimum wages are slightly different in rural and urban areas; however, it is approximately $4 U.S. Dollars per day. Less than one minimum wage 
corresponds to extreme poverty, from 2 to 5 minimum wages are classified as poor people. Cervical Cancer patients often live in extreme poverty.
**All patients had advanced cancer.BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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Table 2: Patients' Perceptions about the Informed Consent
Question Number %
Who invited you to participate in the clinical trial?
My treating physician 30 86
A "new" doctor 41 1
A resident 13
Were you asked to read and sign an informed consent?
Yes 35 100
No 00
Do you know what a consent form is?
A document part of the protocol 23 65
A document that I have to sign before I can be admitted to the study 10 29
An explanation of the treatment 26
Do you know why you were asked to sign the informed consent?
To protect your rights as a patient 00
Because it is a new treatment and can have unwanted effects 8 23
To free the Institution and the doctors of any responsibility in case something bad happens 10 29
To have access to free treatment 16 46
Did you read the document?
Yes 20 57
No 15 43
If not explain why?
I don't know how to read 11 31
The doctor's explanation was enough 92 6
If yes
Once 82 3
More than once 72 0
At home 72 0
At the hospital 82 3
By myself 26
With my family 11 31
After reading the documented, your understanding about the study improved?
Yes 92 6
No 61 7
Do you have any comments about the document?
The document is too long 23 66
The document is difficult to understand 17 49
I could not understand it 17 49
I got bored and did not read it completely 10 29
The doctor explained it to me and i did not read it 11 31
It is a waste of time 12 34
If i don't get into the "protocol, i won't receive any treatment 16 46
I did not understood many of the words 17 49
Why did you decide to participate?
To help others 00
Because the treatment will help me 30 86
To get better 30 86
To increase the knowledge about my disease 00
Because I don't have money to have any other treatment 21 60
Because my Doctor asked me and he knows what is good for me 25 71
Because someone in my family told me 51 4
Because the treatment was free 21 60
I don't know 38
A selection of the relevant questions and answers given by the patients are shown (the complete questionnaires are shown in the appendix). The 
patients and a family member were provided with the questionnaire. It was answered in a quiet room; although study personnel were not present 
in the room at the time, staff members were available outside to answer questions. When required, the questionnaire was read to the illiterate 
patients involved in the research study; otherwise, the patient's family member read out the questions and checked off the selected answer.
Some patients, provided answers not present in the questionnaire.BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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informed about the treatment. All of them answered that
the IC was a requirement of the hospital, the clinical
research organisation, and/or the sponsors' international
authorities and/or an ethical request for research. The
requirement of the informed consent for conducting
research in humans was acknowledged by all doctors;
however, most of them were not sure if and where this
requisite present in the current Mexican Health Law.
None of the doctors had ever participated in an informed
consent design and/or suggested any changes to the spon-
sors, and all of them acknowledge the Declaration of Hel-
sinki as the document that addresses ethical issues for
research involving humans. (Table 3)
To the specific question about "vulnerable population"
the concept was only recognised for children, pregnant
women, prisoners, and those patients living in areas with
access to medical care. Economic educational characteris-
tics, medical condition, situation and desperation for
treatment may offer any hope were not acknowledge as
features of a vulnerable population. Only 15% of the doc-
tors thought that the population the hospital was vulner-
able.
Conflict of interest
Although the physicians conducting the clinical trials
were also the treating doctors, they were unaware of pos-
sible conflicts of interest and did not consider that it inter-
fered with the consent procedure (Table 3).
All the clinical researchers received gifts from the sponsors
(lunches, trips to congresses, etc.), and in most cases
(85%), financial compensation. These circumstances were
not regarded as to influence their ethical behaviour, or to
represent a conflict of interest. Finally, most of the doctors
believed that the patient did not fully understand the
informed consent document (Table 3).
Although questions were not made about moral princi-
ples and ethical behaviour, all of the responding doctors
thought that the survey put in doubt their integrity as phy-
sicians (these arguments were made verbally, no written
complaint was made).
Consent forms
None of the ten consent forms reviewed had a uniform
format; however, all had at the beginning of the docu-
ment the name of the study, sponsors' name and address,
along with the principal investigator's name. Most of the
international clinical trials at the institution were made
for marketing purposes, 10% Phase I, 30% Phase II, and
60% Phase III/IV (data not shown).
Although the studies did not have a uniform description,
all the consent forms fulfilled the basic elements of the
informed consents, as required by international ethical
guidelines. The consent forms were 14 pages long on aver-
age (9–27 pages), and originally written in English (Table
4). Although the overall "technical" accuracy of the trans-
lation was reasonable, the use of scientific words and/or
abbreviations of compounds were the rule; often the
drugs to be studied were mentioned by their brand name.
The presence of medical terms, language not used by non-
medical individuals and words unfamiliar to the popula-
tion that attended the institution were frequently used in
the informed consent (Table 4). For a native Spanish
speaking person, literal translation of the document was
evident and the meaning of some phrases/paragraphs was
difficult to understand. The average readability score of
the ten documents was at an 8TH Grade level (4th-12th
Grade) (Table 4).
The procedures to be applied during the trial were care-
fully described in the consent forms. Often, forms to
request biological samples (tissue, blood, serum) and
authorisations for every thing were included in the same
document. In at least two studies, enrolment was condi-
tioned to the collection of biological samples; one of
them described a DNA analysis and the fact that the
results would not be available to the patients (data not
shown). Comprehension of the consequences of genetic
material requests was not evaluated in this study.
Two sample Consent Forms were chosen to be reviewed
by the ten individuals chosen to assess their comprehensi-
bility. According to one of these individuals (the resi-
dent), the consent form was clear. The rest of the
participants thought that the documents were lengthy,
boring, and too complex to be understood. Most of the
individuals needed to read the forms at least twice; how-
ever, when asked specific questions about the study, only
four participants were able to describe correctly the pur-
pose of the study (Table 5).
Discussion
Public hospitals represent the principal setting for interna-
tionally sponsored research in Mexico; these institutions
provide health care to a sector of the population that has
neither access to social security or private medical atten-
tion. This work exemplifies the characteristics of both,
patients and physicians in this scenery; while doctors are
usually highly professionals (data not shown); most
patients have the lowest income in the country. Further-
more, many of the patients included in this work were liv-
ing in poverty and had a low literacy level (only twenty
percent of the population had high school education or
beyond).BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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In addition, these patients had been receiving treatment
for some time; many of them had advanced disease (data
not shown). Therefore, as is often the case in the setting of
cancer trials for patients with advanced, eventually life
ending disease; the chance of meaningful objective thera-
peutic benefit traditionally has been described as being
quite low [41]. Consequently, even in developed coun-
tries there is a consensus that these patients may be con-
Table 3: Doctors' Responses
Questions No %
What is the purpose of the informed consent?
To inform the patient about the treatment 20 100
A requirement of the hospital authorities 20 100
A requirement of the Mexican health authorities 00
A requirement of the international sponsors 20 100
A requirement of the Clinical Research Organizations (CRO) 20 100
Have you been involved in designing the informed consent?
Yes 00
No 20 100
Are you familiar with the International regulations applied for developing the informed consent procedure?
Yes 00
No 20 100
Is the IC a requirement present in the: Mexican LGS; Mexican Regulation for Research or is it an international request?)*
Is present in the Mexican LGS 20 100
Is present in the Mexican Regulation of Research 00
It is an international requirement 20 100
It is present in all of them 00
Which of the following statements best describes purpose of the informed consent?
A document required for biomedical research 15 75
Guidelines to prepare the informed consent 13 65
A document that will "protect" the physician/researcher in case of legal procedure 15 75
A document to emphasize the "shared" responsibility between doctors and patients 17 85
Not sure 52 5
Do you know what makes a patient vulnerable?
Being a prisoner 20 100
Being poor 00
Being sick 00
Not having medical care 20 100
Do you think that the patients admitted to the hospital are vulnerable?
Yes 31 5
No 17 85
Which of the following conditions may influence the informed consent procedure?
Being the treating physician 00
If the patient is vulnerable 00
Conflict of interest of the physician 20 100
When conducting a clinical trial, are you involved in the patients' treatment before the trial?
Never 00
Sometimes 15
Always 19 95
Did you receive financial compensation from the sponsor company (additional salary, trip, congresses)?
Yes 17 85
No 31 5
Do you think there is a conflict of interest because of this?
Yes 00
No 20 100
Do you think the patient understands the wording of the informed consent?
Yes 73 5
No 13 65
The questionnaires were sent out by e-mail or were delivered in a sealed envelope. The answers were submitted anonymously. Three weeks after 
sending the questionnaire and if a response had not arrived; the physicians were contacted to see if they had sent their responses. Although 70 
questionnaires were sent out, only 20 physicians responded.
* The Mexican Regulation for Research is the document that describes the IC document and tried to document. The purpose of this question was 
to learn about the doctors knowledge about the Mexican regulations, and if they had ever read the regulation.BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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sidered vulnerable populations, and efforts to protect
them from any time of exploitation should be mandatory
[42,43].
It is particularly worrisome the complex setting in which
enrolment of the patients into a research trial takes place;
researchers are also the treating physicians, and often they
have been the patients' doctor for a long period of time. In
this situation, an invitation to a research trial may be
interpreted by many patients to be an endorsement by
their physicians [44].
The ethical consequences of the dual figure – Physician/
researcher – that prevail in the clinical research field have
been extensively addressed. The physician's obligation to
treat patients in a way that will be most beneficial may put
into question their research motives [46-50]. Whether or
not the researcher should be regarded as a doctor, and
whether or not the same obligations should apply to both
doctors and researchers is a matter of debate. While some
authors argue that they must share the same obligations,
there are those who believe that clinical research and ther-
apeutic medical practice are sufficiently distinct activities
to require different ethical rules and principles [51,52].
An important aspect that should be addressed, and a rea-
son of concern from a bioethical perspective worldwide, is
clearly reviewed in this work: the presence of financial ties
between pharmaceutical companies and Mexican oncolo-
gists. Supplemental income provided to researchers by
Table 5: Qualitative Assessment of Comprehensibility
Questions Answers
Did you understand the purpose of the letter? All The answers were yes
What was the study about? 6/10 were unable to describe the purpose of the study
Are there any words that you were unable to understand? 7/10 answered yes
Do you think that the document was clear? Only the medical resident said yes
Were there any medical terms in the document? 10/10 said yes
How many times did you read the document 2/10 read it twice
What do you think about the length of the document 9/10 considered the document lengthy
The comprehensibility of selected consent form was qualitatively scrutinized with the help of ten individuals who had previously agreed to 
participate in the survey. Two nurses (N); two secretaries(S); three ambulance drivers (D); two social workers (SW); and one medical resident(R). 
Selected consent forms were given to read to these individuals after the sponsor's name and study drug(s) were blanked. Afterwards, the short 
questionnaire was handed out, and they were asked to answer all but the second question. Although, all answered that they understood the 
purpose of the study, when asked what it was about, only four answered correctly.
Table 4: Informed Consent Evaluation
Item Average Score (range)
Number of Consent Forms 10
International Requirement for IC All
10/10
Number of pages 14.7
9–27
Original language of the CF E
Accuracy of the translation* 8
6–9
Use of medical or scientific terms** 4.7
2–7
Language unfamiliar to non-medical individuals** 5
2–5
Language unfamiliar to average individual found at the institution** 5.9
Readability Score& 8
4–12
Qualitative evaluation of the Consent forms.
The Consent Forms were individually read and evaluated by a single rater and there is no inter-rater reliability data.
; a numerical value was assigned to some qualitative values using visual scales.
* 1 = poor accuracy ... 10 = good accuracy;
** 1 = few terms or words ... 10 = many terms or words.
Results represent average values and range, when applicable.
&Average value: Non-uniform wording was found; Consent Forms had wording with different readability scores.BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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pharmaceutical companies is common, and gifts as part of
the relation with the industry are the rule. Although the
situation clearly represents a conflict of interest, none of
the physicians questioned recognized that this might
jeopardize a patient's well being in favor of possible
research success [32].
Also, economic influence of international pharmaceutical
companies over physicians needs to be acknowledged. It
is clear that doctors do not believe that gifts, salaries or
trips jeopardize the ethics of their practice; however, mak-
ing it a common practice may eventually be questionable
[32].
The IC procedure is heralded as the principal mechanism
to ensure that research takes place according to ethical
principles. However, IC is a complex and somewhat ideal-
ised process [53]. In order that a valid informed consent is
given, U.S. federal regulations specify eight pieces of infor-
mation that must be disclosed to research participants,
ethically valid informed consent demands more than just
disclosure [54]. Research participants should also under-
stand the essential disclosed information; moreover,
according with O'Neill, consent is a positional attitude, a
ritual that cannot be given by vulnerable populations
[18,55].
The requirement to have an independent decision-mak-
ing, during the IC, is unreal in the clinical setting. Many
patients have diminished independence, particularly at
times when they are most in need of medical care; there-
fore, it is important to open the bioethical view to the
social and medical aspects that are an indivisible part of
the sick [11-17]. In addition; anxiety, stress and the com-
plex information is provided to participants in oncology
clinical trials, requires higher levels of understanding, and
often, patients' do not acknowledge the treatments
offered are experimental [26,27].
If independent decision-making is to be encouraged,
informed consents should be adapted according to the
targeted population [45]. It is clear from the results pre-
sented in this paper that, in few patients, the information
given in these consent forms allows them to give an inde-
pendent and informed decision. The need to consider
social and cultural background, when encouraging 'inde-
pendence' and an equitable doctor-patient relationship, is
of major importance; in some populations, like the one
presented in this work, these actions could be perceived
by the patients as abandonment, as Hedegecoe has argued
[46].
The present work shows that neither the wording nor the
lengths of current IC documents are useful in ensuring a
comprehension of the nature of the research or to help the
patients make an informed and individual decision [58].
In a recent proposal prepared by the American Society of
Clinical Oncology, the creation of a 'central organisation'
to oversee the clinical trials and consent forms has been
suggested [59]. If this proposal is accepted, clinical
researchers from different countries should be aware that
the nature of the informed consent cannot be described in
abstract.
The practice of IC has been driven by two different agen-
das: a legal one and a moral one [53]. In our experience,
sponsoring companies approach informed-consent docu-
ments as compulsory legal regulatory requirements. We
believe that clinical researchers and the Ethics' Commit-
tees should play an active role suggesting the required
changes to the ICF and/or to the way the patients are con-
sented; to guarantee that IC fulfills not only the legal-regu-
latory requirements, but that it is adjusted to the
requirements of the targeted population [54,55].
Several authors have addressed different approaches to
improve the patients' comprehension of experimental
treatments; the time with the potential participant seems
to be the best way to improve the understanding of the
patients [55,60-62]. It is also important to acknowledge
that these patients should be considered a vulnerable pop-
ulation and proper actions should be implemented to
protect them, without depriving them from the benefits of
experimental treatments. In the setting of developing
countries, important considerations should be made
regarding the informed consent. Even if the procedure fol-
lows the established guidelines of 'Good Clinical Practice'
it may not accomplish its purpose when a vulnerable non-
autonomous population is being consented.
We are aware of the study limitations; these findings may
not be representative of all the settings within the country,
in some clinical settings the populations have higher edu-
cational levels; however, most clinical trials are conducted
in public hospitals where the average population may
have similar characteristics to those described in this
work.
Recommendations
The need to redress the balance of the informed consent,
so that the ethical process is simple, concentrates on the
rights of individuals and is institutionally mandatory
[55]. The use of short video capsules about patients' rights
could be arranged in different waiting areas of the institu-
tions; language should be respectful and simple according
to the educational level of the average population. The
exposure to these materials could make it simpler for
them to recognise when they are being invited to be part
of a research trial, sometimes long before other types of
treatments have failed.BMC Medical Ethics 2006, 7:13 http://www.biomedcentral.com/1472-6939/7/13
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In addition, researchers should be aware that the
informed consent is a procedure needed to establish a
respectful and ethical relation between doctors and
patients.
Conclusion
There is no simple answer to the inevitable question of
'how valid is the informed consent for these patients?' But
it is clear that some adjustments should be implemented,
accordingly with the characteristics' described in this pop-
ulation.
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